Tags

Type your tag names separated by a space and hit enter

Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
Int J Cardiol. 2006 Jun 16; 110(2):276-7.IJ

Abstract

The available data have suggested a significant association between hypertriglyceridemia and cardiovascular disease. Although atherogenic dyslipidemia in patients with metabolic syndrome is characterized by high triglyceride, low HDL cholesterol and near normal LDL cholesterol levels, lowering LDL cholesterol is the first priority in treating dyslipidemia in patients with metabolic syndrome. The use of statins as monotherapy is still leaving some of these patients with mixed atherogenic dyslipidemia at high risk for coronary events. So, it seems beneficial to add a fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome, especially in patients with inadequately corrected triglyceride levels with statin monotherapy.

Authors

Turhan H
No affiliation info available
Yetkin E
No affiliation info available

MeSH

Clofibric AcidDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMetabolic Syndrome

Pub Type(s)

Letter

Language

eng

PubMed ID

16364471

Citation

Turhan, Hasan, and Ertan Yetkin. "Is It Necessary to Add Fibrate to Statin Therapy in the Management of Dyslipidemia of Metabolic Syndrome?" International Journal of Cardiology, vol. 110, no. 2, 2006, pp. 276-7.
Turhan H, Yetkin E. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome? Int J Cardiol. 2006;110(2):276-7.
Turhan, H., & Yetkin, E. (2006). Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome? International Journal of Cardiology, 110(2), 276-7.
Turhan H, Yetkin E. Is It Necessary to Add Fibrate to Statin Therapy in the Management of Dyslipidemia of Metabolic Syndrome. Int J Cardiol. 2006 Jun 16;110(2):276-7. PubMed PMID: 16364471.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome? AU - Turhan,Hasan, AU - Yetkin,Ertan, Y1 - 2005/12/20/ PY - 2005/10/01/received PY - 2005/11/05/accepted PY - 2005/12/21/pubmed PY - 2006/11/3/medline PY - 2005/12/21/entrez SP - 276 EP - 7 JF - International journal of cardiology JO - Int J Cardiol VL - 110 IS - 2 N2 - The available data have suggested a significant association between hypertriglyceridemia and cardiovascular disease. Although atherogenic dyslipidemia in patients with metabolic syndrome is characterized by high triglyceride, low HDL cholesterol and near normal LDL cholesterol levels, lowering LDL cholesterol is the first priority in treating dyslipidemia in patients with metabolic syndrome. The use of statins as monotherapy is still leaving some of these patients with mixed atherogenic dyslipidemia at high risk for coronary events. So, it seems beneficial to add a fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome, especially in patients with inadequately corrected triglyceride levels with statin monotherapy. SN - 0167-5273 UR - https://www.unboundmedicine.com/medline/citation/16364471/Is_it_necessary_to_add_fibrate_to_statin_therapy_in_the_management_of_dyslipidemia_of_metabolic_syndrome DB - PRIME DP - Unbound Medicine ER -